机构

• 上海药物研究所 [4]

采集方式

• OAI收割 [4]

内容类型

• 期刊论文 [4]

发表日期

• 2021 [1]
• 2014 [1]
• 2013 [2]

学科主题

筛选

浏览/检索结果: 共4条，第1-4条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择题名升序题名降序提交时间升序提交时间降序作者升序作者降序发表日期升序发表日期降序 Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells 期刊论文  OAI收割 THORACIC CANCER, 2021, 页码: 9 作者:  Zhang, Mi;  Quan, Haitian;  Fu, Li;  Li, Yun;  Fu, Haoyu   |  收藏  |  浏览/下载：66/0  |  提交时间：2021/05/24 EGFR‐  mutant non‐  small cell lung cancer  famitinib  HS‐  10296  multi‐  targeted tyrosine kinase inhibitor  third‐  generation EGFR inhibitor   Predicting pharmacokinetics of anti-cancer drug, famitinib in human using physiologically based pharmacokinetic model 期刊论文  OAI收割 Acta Pharmaceutica Sinica, 2014, 卷号: 49, 期号: 12, 页码: 1684-1688 作者:  Yu Mingming;  Gao Zhiwei;  Chen Xiaoyan;  Zhong Dafang   |  收藏  |  浏览/下载：43/0  |  提交时间：2019/01/08 famitinib  physiologically based pharmacokinetic model  species extrapolation  tyrosine kinase inhibitor   Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib 期刊论文  OAI收割 CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 卷号: 72, 期号: 5, 页码: 1043-1053 作者:  Zhou, Aiping;  Zhang, Wen;  Chang, Chunxiao;  Chen, Xiaoyan;  Zhong, Dafang   |  收藏  |  浏览/下载：51/0  |  提交时间：2019/01/08 Famitinib  Phase I trial  Safety  Pharmacokinetics  Antitumor activity   Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients 期刊论文  OAI收割 BRITISH JOURNAL OF PHARMACOLOGY, 2013, 卷号: 168, 期号: 7, 页码: 1687-1706 作者:  Xie, Cen;  Zhou, Jialan;  Guo, Zitao;  Diao, Xingxing;  Gao, Zhiwei   |  收藏  |  浏览/下载：62/0  |  提交时间：2019/01/08 famitinib  metabolism  bioactivation  quinone-imine  hepatotoxicity